加载中
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
常规交易时段
US$39.875
−US$0.325 · -0.81%
盘中时间采用ET。市场数据可能有所延迟。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日内区间
当前US$39.875
52周区间
当前US$39.875
盘中时间采用ET。市场数据可能有所延迟。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日内区间
当前US$39.875
52周区间
当前US$39.875
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 467.16亿 EUR | 442.86亿 EUR | 416.18亿 EUR | 405.61亿 EUR | 391.75亿 EUR |
| 销货成本 | 130.49亿 EUR | 132.05亿 EUR | 126.28亿 EUR | 118.82亿 EUR | 122.55亿 EUR |
| 毛利 | 336.67亿 EUR | 310.81亿 EUR | 289.9亿 EUR | 286.79亿 EUR | 269.2亿 EUR |
| 研究与开发 | 78.42亿 EUR | 73.94亿 EUR | 65.07亿 EUR | 65.01亿 EUR | 56.92亿 EUR |
| 销售、一般及管理费用 | 102.42亿 EUR | 91.83亿 EUR | 89.33亿 EUR | 87.39亿 EUR | 95.55亿 EUR |
| 营业费用 | 240.7亿 EUR | 238.29亿 EUR | 220.3亿 EUR | 185.17亿 EUR | 187.94亿 EUR |
| 利息收入 | 3.31亿 EUR | 4.58亿 EUR | 5.31亿 EUR | 1.69亿 EUR | 312.7万 EUR |
| 利息支出 | 6.26亿 EUR | 6.23亿 EUR | 5.13亿 EUR | 3.85亿 EUR | 3.77亿 EUR |
| 折旧和摊销 | 56.78亿 EUR | 35.86亿 EUR | 44.29亿 EUR | 31.08亿 EUR | 33.51亿 EUR |
| 营业利润 | 95.97亿 EUR | 72.52亿 EUR | 69.6亿 EUR | 101.62亿 EUR | 81.26亿 EUR |
| 净利润 | 78.13亿 EUR | 55.6亿 EUR | 54亿 EUR | 83.71亿 EUR | 62.23亿 EUR |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$49.50
上涨空间 24.14%年度分割调整后的每股现金分配。
US$2.1953
2025年（完整年度）+15.2% 自从 2021
2026年（部分年度）：US$2.419
US$1.906
2,021
US$2.044
2,022
US$1.903
2,023
US$2.0369
2,024
US$2.1953
2,025
US$2.419
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年5月4日 | US$2.419Annual | 2026年5月4日 | 2026年6月3日 |
股息 | 2025年5月9日 | US$2.1953Annual | 2025年5月9日 | 2025年6月12日 |
股息 | 2024年5月9日 | US$2.0369Annual | 2024年5月10日 | 2024年6月6日 |
股息 | 2023年5月30日 | US$1.903Annual | 2023年5月31日 | 2023年6月23日 |
股息 | 2022年5月26日 | US$0.297Special | 2022年5月27日 | 2022年6月27日 |
股息 | 2022年5月4日 | US$1.747Annual | 2022年5月5日 | 2022年5月31日 |
除息 2026年5月4日
US$2.419
Annual
2026年5月4日登记 · 支付日 2026年6月3日
除息 2025年5月9日
US$2.1953
Annual
2025年5月9日登记 · 支付日 2025年6月12日
除息 2024年5月9日
US$2.0369
Annual
2024年5月10日登记 · 支付日 2024年6月6日
除息 2023年5月30日
US$1.903
Annual
2023年5月31日登记 · 支付日 2023年6月23日
除息 2022年5月26日
US$0.297
Special
2022年5月27日登记 · 支付日 2022年6月27日
除息 2022年5月4日
US$1.747
Annual
2022年5月5日登记 · 支付日 2022年5月31日
报告持有此股票敞口的交易所交易基金。
Avantis International Equity ETFAVDE3998.44万0.21%192.77亿 USD0.23%US$89.075-0.45%
Fidelity Enhanced International ETFFENI3510.46万0.30%114.7亿 USD0.28%US$39.44-0.53%
VanEck Pharmaceutical ETFPPH3297.69万3.25%10.28亿 USD0.36%US$107.42-1.89%
First Trust Value Line Dividend Index FundFVD3001.93万0.40%75.97亿 USD0.62%US$47.09+0.00%
Invesco International Dividend Achievers ETFPID2464.24万2.89%8.54亿 USD0.53%US$21.52+0.14%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH1922.14万1.88%10.3亿 USD0.13%US$27.61-2.07%
GMO International Value ETFGMOI1630.77万2.50%6.61亿 USD0.60%US$38.98-0.20%
Brown Advisory Sustainable Value ETFBASV604.11万1.48%4.09亿 USD0.71%US$30.2592-0.17%Avantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDInvesco International Dividend Achievers ETFPIDPortfolio Building Block World Pharma and Biotech Index ETFPBPHGMO International Value ETFGMOIBrown Advisory Sustainable Value ETFBASVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
